Supraoptimal Peptide–Major Histocompatibility Complex Causes a Decrease in Bcl-2 Levels and Allows Tumor Necrosis Factor α Receptor II–mediated Apoptosis of Cytotoxic T Lymphocytes

Cytotoxic T lymphocytes (CTLs) are primary mediators of viral clearance, but high viral burden can result in deletion of antigen-specific CTLs. We previously reported a potential mechanism for this deletion: tumor necrosis factor (TNF)-α–mediated apoptosis resulting from stimulation with supraoptimal peptide–major histocompatibility complex. Here, we show that although death is mediated by TNF-α and its receptor (TNF-RII), surprisingly neither the antigen dose dependence of TNF-α production nor that of TNF-RII expression can account for the dose dependence of apoptosis. Rather, a previously unrecognized effect of supraoptimal antigen in markedly decreasing levels of the antiapoptotic protein Bcl-2 was discovered and is likely to account for the gain in susceptibility or competence to sustain the death signal through TNF-RII. This decrease requires a signal through the TCR, not just through TNF-RII. Although death mediated by TNF-RII is not as widely studied as that mediated by TNF-RI, we show here that it is also dependent on proteolytic cleavage by caspases and triggered by a brief initial encounter with antigen. These results suggest that determinant density can regulate the immune response by altering the sensitivity of CTLs to the apoptotic effects of TNF-α by decreasing Bcl-2 levels.

[1]  H. Rammensee,et al.  Protective Immunity Does Not Correlate with the Hierarchy of  Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides , 1998, The Journal of experimental medicine.

[2]  Soo Young Lee,et al.  A Regulatory Role for TRAF1 in Antigen-induced Apoptosis of  T Cells , 1997, The Journal of experimental medicine.

[3]  J. Yuan,et al.  Transducing signals of life and death. , 1997, Current opinion in cell biology.

[4]  P. Henkart,et al.  Different Interleukin-1β Converting Enzyme (ICE) Family Protease Requirements for the Apoptotic Death of T Lymphocytes Triggered by Diverse Stimuli , 1996, The Journal of experimental medicine.

[5]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[6]  S. Nagata,et al.  Apoptosis: Telling cells their time is up , 1996, Current Biology.

[7]  J. Berzofsky,et al.  Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL , 1996, The Journal of experimental medicine.

[8]  A. Chinnaiyan,et al.  The cell-death machine , 1996, Current Biology.

[9]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Mike Rothe,et al.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins , 1995, Cell.

[11]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[12]  M. Lenardo,et al.  Induction of apoptosis in mature T cells by tumour necrosis factor , 1995, Nature.

[13]  L. Zheng,et al.  Analysis of the CD4 coreceptor and activation-induced costimulatory molecules in antigen-mediated mature T lymphocyte death. , 1995, Journal of immunology.

[14]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[15]  A. Strasser,et al.  Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. , 1995, Current opinion in immunology.

[16]  R. Weichselbaum,et al.  Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. , 1995, Cancer research.

[17]  D. Margulies,et al.  Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. , 1995, Journal of immunology.

[18]  D. Goeddel,et al.  Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75 , 1995, The Journal of experimental medicine.

[19]  M. Bevan,et al.  Specificity and flexibility in thymic selection , 1994, Nature.

[20]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[21]  J. Goverman,et al.  T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. , 1994, Science.

[22]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[23]  D. Adams,et al.  Protease inhibitors selectively block T cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells , 1993, The Journal of experimental medicine.

[24]  V. Stewart,et al.  Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. , 1993, Science.

[25]  Mike Rothe,et al.  Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor , 1993, Cell.

[26]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[27]  J. Berzofsky,et al.  Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules , 1992, The Journal of experimental medicine.

[28]  M. Lenardo.  lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.

[29]  J. Berzofsky,et al.  Excess β2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules , 1991, Nature.

[30]  B. Moss,et al.  CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[32]  B. Autran,et al.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. , 1989, Journal of immunology.

[33]  C. DeLisi,et al.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Nowell,et al.  Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. , 1987, Science.

[35]  N. Mitchison,et al.  Induction of immunological paralysis in two zones of dosage , 1964, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[36]  C. Ware,et al.  Apoptosis mediated by the TNF‐related cytokine and receptor families , 1996, Journal of cellular biochemistry.

[37]  M. Lenardo,et al.  Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. , 1995, Cellular immunology.

[38]  Rolf M. Zinkernagel,et al.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.

[39]  M S Doscher,et al.  Solid-phase peptide synthesis. , 1977, Methods in enzymology.